Takeda's subcutaneous Entyvio meets in Phase III for maintenance therapy of ulcerative colitis

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said subcutaneous Entyvio vedolizumab as maintenance therapy met the primary endpoint vs. placebo in the Phase III VISIBLE 1 trial to treat ulcerative colitis in patients who achieved a clinical response at week six following two doses of open-label IV Entyvio as induction therapy.

On the primary endpoint, a significantly greater proportion of patients who received maintenance subcutaneous Entyvio starting at week six and every two weeks thereafter achieved clinical remission, defined as a complete Mayo score of ≤2 points and no individual subscore of greater than >1 point, at week 52 vs. placebo...